These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 36739653)

  • 1. PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives.
    Nicholls SJ
    Kardiol Pol; 2023; 81(2):115-122. PubMed ID: 36739653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M
    Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update on PCSK9 inhibition].
    Katzmann JL; Custodis F; Schirmer SH; Laufs U
    Herz; 2022 Jun; 47(3):196-203. PubMed ID: 35445838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations.
    Stürzebecher PE; Laufs U
    Curr Opin Lipidol; 2024 Aug; 35(4):179-186. PubMed ID: 38547336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
    Bittner VA; Giugliano RP; Brinton EA; Guyton JR
    J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
    Scheen AJ; Wallemacq C; Lancellotti P
    Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
    Warden BA; Duell PB
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran.
    Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR
    J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 inhibitors: current status and emerging frontiers in lipid control.
    Agnello F; Mauro MS; Rochira C; Landolina D; Finocchiaro S; Greco A; Ammirabile N; Raffo C; Mazzone PM; Spagnolo M; Occhipinti G; Imbesi A; Giacoppo D; Capodanno D
    Expert Rev Cardiovasc Ther; 2024; 22(1-3):41-58. PubMed ID: 37996219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Pharmacological Approaches to Target PCSK9.
    Catapano AL; Pirillo A; Norata GD
    Curr Atheroscler Rep; 2020 Jun; 22(7):24. PubMed ID: 32495301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 inhibitors in the prevention of cardiovascular disease.
    Latimer J; Batty JA; Neely RD; Kunadian V
    J Thromb Thrombolysis; 2016 Oct; 42(3):405-19. PubMed ID: 27095708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives.
    Cho KH; Hong YJ
    Korean J Intern Med; 2020 Sep; 35(5):1045-1058. PubMed ID: 32921006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.